Question 1

What can the Click.mAb. platform do?

Accepted Answer

Click.mAb. is a multi-agent AI antibody design platform developed by Clickmab. Core capabilities include: de novo antibody design for specific epitopes, epitope prediction, antibody/nanobody humanization, and affinity maturation. It supports the full workflow from natural language R&D goals to AI-driven task decomposition, tool orchestration, and structured report generation.

Question 2

What is the success rate of de novo design? Is there experimental validation?

Accepted Answer

Validated on 4 targets. After designing ~10,000 candidates for specified epitopes, wet-lab validation yielded multiple hits with affinity ranging from μM to nM. The best case produced 7 BLI-positive antibodies (KD 10⁻⁶~10⁻⁸ M), 2 with ligand-blocking function, confirmed by cryo-EM.

Question 3

What is the accuracy of epitope prediction?

Accepted Answer

Our INSPIRE-SEEN model achieves 78% patch binary classification accuracy on 110 known epitopes, a 28-point improvement over AlphaFold2-Multimer's 50%. Each prediction takes ~15 minutes at over 100x lower cost than traditional wet-lab methods.

Question 4

What are the advantages of AI affinity maturation?

Accepted Answer

Compared to traditional random mutagenesis, AI affinity maturation uses structure-aware models to precisely predict beneficial mutations, requiring fewer candidates to cover high-gain designs and dramatically reducing wet-lab rounds. It also balances stability and developability to avoid aggregation or expression issues.

Question 5

How does AI antibody design differ from traditional animal immunization?

Accepted Answer

Traditional methods rely on animal immunization, favoring immunodominant epitopes with limited coverage of cryptic or low-immunogenicity epitopes. AI de novo design bypasses immunization entirely, generating novel antibodies directly targeting specified epitopes for precise rational design.

Question 6

How effective is humanization?

Accepted Answer

Antibody humanization achieves 90%–95% humanness with zero back-mutations needed, requiring only 10–20 candidates. Nanobody humanization reaches 89%–94%, with 4 out of 7 recommended sequences showing improved affinity, best improving from 16 nM to ~4 nM.

Question 7

What data is needed to use the platform?

Accepted Answer

Input varies by module: de novo design requires antigen structure and target epitope; epitope prediction needs antigen structure (PDB) and antibody sequences (VH/VL); humanization needs variable region sequences; affinity maturation needs antigen and antibody sequences. The platform guides you through input.

Question 8

How to get started?

Accepted Answer

Visit clickmab.com to register and try epitope prediction and de novo design online. For full project collaboration (including wet-lab validation), contact our business team at bd@clickmab.com for a customized solution.

Core AI Capabilities for Antibody Discovery

Lightweight Tools

Epitope Prediction

De Novo Antibody Design

CDR Diversity Engineering

Affinity Maturation

Antibody Humanization

Nanobody Humanization

AI-Native Antibody Discovery Platform

One Sentence to Launch R&D

Project-Level Collaboration for Research Teams

Parallel Workflow Management

Independent Validation & Collaborative Research

Automatic Knowledge Repository

Reusable, Traceable, and Transferable

A Complete Closed-Loop Workflow from Candidate Generation to Experimental Validation

Epitope-Guided Design

Structure & Sequence Assessment

Experimental Validation

Project Asset Management

FAQ

Start Your AI-Driven Antibody R&D Journey